

Presidio HCC Module

The application manages patients with HCC, the most common type of liver cancer

ACTIVITIES

- Evaluation
- Diagnosis
- Treatment plan
- Tumor stage
- Treatment
- Follow-up
- Reports

EMR features

- Patient demography
- Insurance
- Encounter/visit
- Diagnostic studies
- Medication/prescription
- Memos
- Scanned documents and images

Liver malignancy, one of the major causes for liver transplantation, can affect the medical urgency of a patient on the wait list by allowing an increase of the MELD score. The Presidio HCC (Hepatocellular Carcinoma) application has been developed to help manage patients with HCC and to address UNOS wait list urgency criteria.

The application covers the the following activities:

- Preliminary evaluation—medical history and preliminary exam
- Radiology testing—PET scan, CT scan, Ultrasound and/or MRI
- Pathology testing
- Tumor stages
- Treatment plan
- Treatment and follow-up

EVALUATION

- Captures medical history and records data on abdominal complaints
- Examination for enlargement of liver
- Blood work

RADIOLOGY TESTING

Reporting functionality that includes: location (segment), signal intensity, dynamic series, lesion definition, vascular thrombus and other measurement scores such as LRI, Milan and UCSF criteria.

PATHOLOGY TESTING

Reporting functionality includes all of the data required by UNOS and the number of tumors and locations.

The pathological data maps to the required UNOS “Liver Recipient Explant Pathology” report.

Radiology

Type Of Exam: CT Scan US Abdominal PET Scan MRI

Date Of Observation: 4/30/2012 15 Time: 08:26 AM


Accession #: A671

Bilateral: Yes No

Remarks: Clear Test evidence

Meets Milan Criteria: Yes No

Meets Expanded (UCSF) Criteria: Yes No



| | Segment 4b | Segment 6 | Segment 7 |
|--------------------|------------|--------------|--------------|
| Image #/Series # | | | |
| Lesion # | 2 | 1 | 1 |
| HCC Tumor Id | 1 | 2 | 1 |
| Dominant segment | Segment 7 | | |
| Signal Features | | | |
| SI T1 pre-contrast | | well defined | well defined |

Pathology

Accession #: AC471

| Tumor Number | Location | Margin Status | Width of Margin | Tumor Size | Tumor Grade | Vascular Invasion | Necrosis | Differentiation | HCC Tumor ID |
|--------------|----------|---------------|-----------------|------------|-------------|-------------------|------------|-----------------|--------------|
| 1 | Right | N | | 3 | G1 | microvascular | None | Moderate | 1 |
| 2 | Right | P | 1 | 4 | G2 | macrovascular | Incomplete | Poor | 2 |

Evidence Of HCC in explant: Yes No

Number Of Tumors: 2

Infiltrative: Yes No

Satellite Lesions: Yes No

Pre-Transplant Treatment Of HCC: Yes No

Other Extrahepatic Spread: Yes No

Fibrolamellar:

Non-Tumorous Liver: Steatosis steatohepatitis fibrosis cirrhosis

Fibrosis Grade: 1 0 1 2 3 4

Lymph Node Count: 1

Lymph Node Involvement: Yes No

Presidio HCC Module

COMPANY HISTORY

TeleResults was founded in 1995 and is based in San Francisco. The company is a proven leader in organ disease and transplant management software. Through collaboration and close partnership with customers, TeleResults continues to enhance its applications and adds new disease management and organ support tools. TeleResults has an unparalleled commitment to customer satisfaction and a loyal, growing customer base. TeleResults regularly updates their applications to meet the evolving needs of medical centers and to help them maintain regulatory compliance.

TUMOR STAGES

Tumor stages can be defined based on the TNM data entered by analyzing the diagnostic test data.

Surgical screen

TREATMENT PLAN, TREATMENT, AND FOLLOW-UP

Tumors discovered by radiology and/or pathology testing can have specific treatments that may be tailored to an individual tumor.

The treatment plan is defined and recorded initially and can change over time. The plan can include one or more of the following courses of treatment:

- Interventional radiology
- Chemotherapy
- Surgical

The specific details of each applied treatment can be recorded as well.

TECHNICAL INFORMATION

TeleResults Presidio HCC Module utilizes MSQQL Server, an ODBC compliant database that allows commercial applications to access the data for report generation, statistical analysis and custom queries.

UNOS "Liver Recipient Explant Pathology" report



TeleResults Corporation

Flood Building, 870 Market Street, Suite 556 • San Francisco, CA 94102-3016

TEL 415.392.9670 • FAX 415.392.9674 • TOLL FREE 800.909.9625

Contact: info@teleresults.com • www.teleresults.com